نتایج جستجو برای: pd l2

تعداد نتایج: 79105  

2014
JanisM. Taube Julie R. Brahmer Haiying Xu Drew M. Pardoll Suzanne L. Topalian Robert A. Anders

Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide patient selection and therapeutic optimization. Experimental Design: Patients (N 1⁄4 41) with melanoma, non–small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma, or castration-resistant prostate cancer...

2015
Robert Chen Phillippe Armand Michelle A Fanale Vincent Ribrag Pier Luigi Zinzani Alejandro D Ricart Seth Thompson Arun Balakumaran Daniel Molin Margaret A Shipp Craig H Moskowitz

Background The prognosis is poor for patients with cHL who relapse after autologous stem-cell transplant (auto-SCT) or progress after brentuximab vedotin (BV) therapy. cHL frequently harbors genetic amplification at 9p24.1, which leads to overexpression of PD-L1 and PD-L2 on the tumor cell surface. This suggests that cHL may have a genetically determined dependence on the PD-1 pathway for survi...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Janis M Taube Alison Klein Julie R Brahmer Haiying Xu Xiaoyu Pan Jung H Kim Lieping Chen Drew M Pardoll Suzanne L Topalian Robert A Anders

PURPOSE Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide patient selection and therapeutic optimization. EXPERIMENTAL DESIGN Patients (N = 41) with melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma, or castration-resistant prostate cancer w...

2014
JanisM. Taube Julie R. Brahmer Haiying Xu Drew M. Pardoll Suzanne L. Topalian Robert A. Anders

Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide patient selection and therapeutic optimization. Experimental Design: Patients (N 1⁄4 41) with melanoma, non–small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma, or castration-resistant prostate cancer...

2017
Yuan Gao Su Li Dazhi Xu Shangxiang Chen Yuchen Cai Wenqi Jiang Xinke Zhang Jin Sun Kefeng Wang Boyang Chang Fenghua Wang Minghuang Hong

BACKGROUND Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials. However, the value of PD-L1 in predicting responses of patients with gastric cancer to anti-PD-1/PD-L1 immunotherapy is controversial. Some studies suggested that intra- and inter-tumoral heterogeneity of PD-L1 expression might exp...

Journal: :Inorganica Chimica Acta 2021

Abstract New thiosemicarbazone (TSC) ligands, AMT-C N-TSCH (L1), N-TSC(CH3) (L2), CIN-C (L3) and (L4) (AMT = 2-acetyl-5-methylthiophene, TSCH = thiosemicarbazide, TSC(CH3) = 4-methyl-3-thiosemicarbazide, CIN = cinnamaldehyde) were synthesized by condensation reaction. The reaction of [PdCODCl2] with the ligands L1, L2 L4in ratio 1:1 yielded complexes [Pd(L1)Cl] (C1), [Pd(L2)Cl2] (C2), [Pd(L4)2C...

2015
Syeda S. Hassan Muhammad Akram Elizabeth C. King Hazel M. Dockrell Jacqueline M. Cliff Francesco Dieli

BACKGROUND The PD-1 axis is a cell intrinsic immunoregulatory pathway that mediates T cell exhaustion in chronic infection particularly in some viral infections. We hypothesized that PD-1, PD-L1 and PD-L2 would be highly expressed in untreated tuberculosis patients compared to controls due to their chronic infection and would decrease with successful TB treatment. MATERIALS AND METHODS Untrea...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید